TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
32.21
+0.32 (1.00%)
At close: Sep 5, 2025, 4:00 PM
32.72
+0.51 (1.58%)
Pre-market: Sep 8, 2025, 8:00 AM EDT
TG Therapeutics Revenue
TG Therapeutics had revenue of $141.15M in the quarter ending June 30, 2025, with 92.13% growth. This brings the company's revenue in the last twelve months to $454.07M, up 30.96% year-over-year. In the year 2024, TG Therapeutics had annual revenue of $329.00M with 40.80% growth.
Revenue (ttm)
$454.07M
Revenue Growth
+30.96%
P/S Ratio
10.35
Revenue / Employee
$1,343,399
Employees
338
Market Cap
4.70B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
Dec 31, 2020 | 152.00K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TGTX News
- 56 minutes ago - TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment - GlobeNewsWire
- 4 days ago - TG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 days ago - TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 days ago - TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program - GlobeNewsWire
- 11 days ago - TG Therapeutics to Participate in the Cantor Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance - GlobeNewsWire
- 5 weeks ago - TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire